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Before the menopause cardiovascular events are less frequent in women than in men. This suggests a protective role for oestrogens. This apparent protection disappears in diabetes [10] . Oestrogen replacement therapy (ERT) in non-diabetic women after the menopause was found to be associated with lower fasting glucose [11] and with lower insulin concentrations [11, 12] . Godsland et al. [13] found no significant difference between users of ERT and non-users. They estimated insulin sensitivity by mathematical modelling of intravenous glucose tolerance tests. Lindheim et al. [14] using insulin tolerance tests found only a difference for low dose conjugated oestrogens. In experimental animal studies lowering of blood glucose induced by insulin was enhanced oestrogen therapy [15, 16] . Recently the Postmenopausal Estrogen/Progestin Interventions (PEPI)-trial [17] , a placebo controlled double blind study in non-diabetic women, showed a significant decrease of fasting glucose during oral treatment with conjugated equine oestrogens with no change in insulin levels.
ERT was associated with a 50 % reduction of the relative risk in cardiovascular morbidity and mortality in observational studies in non-diabetic women [18] . Selection bias may have caused overestimation of the apparent protective effect of ERT [19] . However, both the observation in animal studies that oestrogens stimulate reverse cholesterol transport with decreased subintimal cholesterol ester accumulation [20] and the direct vasorelaxing effect of oestrogens seen in humans [21] strongly suggest a beneficial effect. Moreover, during ERT the lipoprotein profile [22] and parameters of fibrinolysis [23] changed favourably.
In diabetic postmenopausal women ERT is only reluctantly advised [24] . The adverse effects of oral contraceptives on glucose tolerance in patients with NIDDM [25] may have contributed to the hesitation.
We studied the short term effects of ERT on glycaemic control and on insulin resistance using the euglycaemic hyperinsulinaemic clamp in relation with their effects on lipoprotein profile and fibrinolysis in patients with NIDDM with normal or elevated plasma triglyceride level (cut-off 2.0 mmol/l).
Subjects and methods
Patients. We recruited 40 postmenopausal women with NIDDM from outpatient clinics of the University Hospital Leiden or by advertisements and articles in newspapers. We considered NIDDM to be present if diabetes had been controlled sufficiently with diet and/or oral hypoglycaemic agents for more than 1 year or when detectable plasma C-peptide concentrations after glucagon stimulation were found. Women were considered to be postmenopausal when they had no menstrual cycle for more than 1 year. This was confirmed biochemically by a concentration of follicle stimulating hormone (FSH) in plasma over 20 U/l, higher concentrations of FSH than luteinising hormone (LH) and a concentration of oestradiol under 50 pmol/l. Exclusion criteria were: manifest coronary heart disease; liver or renal impairment; endocrine abnormalities other than NIDDM; hereditary diseases of lipid metabolism, plasma triglyceride levels over 10 mmol/l; oestrogen sensitive tumours or a history of thromboembolic diseases. Also excluded were patients who used metformin, diuretics, lipid lowering drugs, corticosteroids, anticonvulsant therapy or postmenopausal hormonal replacement therapy within the previous 3 months. The study was approved by the committee of medical ethics of the University Hospital Leiden and all women gave informed consent before their entry to the study.
Study protocol. We conducted a 6-week double blind placebo controlled trial of 2 mg micronized 17-b oestradiol (Novo-Nordisk, Zoeterwoude, The Netherlands) in 40 postmenopausal women with NIDDM, who received once daily either ERT or placebo orally. The patients were randomized into two groups of 20 subjects. Randomization was performed by a pharmacist, who was the only person knowing the code. FSH and LH were measured after closure of the trial in order not to break the code indirectly. We postulated that the effect of ERT would be similar in the normotriglyceridaemic group (NTG, TG K 2 mmol/l; n = 27) and the hypertriglyceridaemic group (HTG, TG > 2 mmol/l; n = 13). In the NTG group 14 patients received oestrogen and 13 patients placebo. In the HTG group 6 patients were treated with oestrogen and 7 with placebo. The patients were asked to keep a food diary. Before and after 6 weeks of treatment parameters of insulin resistance, lipoprotein metabolism and fibrinolysis were assessed. After the study all patients were treated with 5 mg medroxyprogesterone acetate orally except those who had undergone a hysterectomy in the past.
Two patients from the oestrogen-group reported vaginal spotting, for which they were referred to the gynaecological department. They did not withdraw from the study.
Metabolic investigations. All patients were admitted to the metabolic ward the day before the clamp study. To achieve euglycaemia regular insulin was infused intravenously during the overnight fasting period. At 08.00 hours a cannula was inserted in the other forearm for blood sampling. The arm was placed in a thermoregulated plexiglass box (50-70°C) to obtain arterialized blood. Before the start of the clamp blood samples were drawn for the assessment of fibrinolytic parameters and lipoprotein profile.
A sequential euglycaemic (5.4 mmol/l) hyperinsulinaemic three-step clamp was performed in order to measure whole body glucose uptake (WBGU) at various insulin perfusion rates [6] . To assess the hepatic glucose production rate (HGP) we administered tritiated glucose (3-3 H-glucose, specific activity 499.5 GBq/mmol, NET-331C; Dupont, Boston, Mass., USA). as a tracer by fixed infusion in a rate of 10 m Ci/h for 6 h, preceded by a bolus of 15 m Ci. During the clamp study plasma glucose was determined every 5 min (Glucose analyser; Beckman Instruments, Palo Alto, Calif., USA). The duration of each step of the clamp was 2 h. During the last 30 min of each step (the equilibrium phase) four blood samples were drawn to estimate the insulin concentration and the specific activity of glucose. The concentration of non-esterified fatty acid (NEFA) was determined in the last blood sample of each step. A dose response curve was obtained by infusion of regular insulin in the following order: 1) basal step: as much insulin as needed to maintain euglycaemia; 2) second step: 1.25 mU ⋅ kg −1 ⋅ min −1 , preceded by a bolus of 12.5 mU ⋅ kg −1 ; and 3) third step: 10 mU ⋅ kg
, preceded by a bolus of 100 mU ⋅ kg −1 . During the last two steps 20 % glucose was infused to maintain euglycaemia. Forty to sixty mmol potassium chloride was added to 1000 ml glucose 20 % solution to prevent hypokalaemia.
In the first step of the clamp WBGU was equal to HGP. In the next two steps WBGU was calculated according to the isotope dilution technique, being the quotient between the infusion rate of tritiated glucose and the specific activity of glucose in plasma. The specific activity is the quotient between 3-3 H glucose in counts per minute and m mol glucose in the same aliquots. The specific activity of tritiated glucose was assessed after deproteinizing plasma with ZnSO 4 and Ba(OH) 2 .
The HGP in the second and third step of the clamp was calculated by subtracting the mean glucose infusion rate during the last 30 min from the calculated rate as mentioned above. In the third step HGP was zero. HGP suppression (HGP suppr ) was calculated as (HGP 1 -HGP 2 )/HGP 1 (where HGP 1 denotes HGP in step 1 and HGP 2 denotes HGP in step 2 of the three step clamp). The mean glucose infusion rate during the steady state of second and the third step was considered to be the WBGU if the mean glucose infusion rate exceeded the quotient between the infusion rate of tritiated glucose and the specific activity of glucose. Otherwise the WBGU was assumed to be equal to the above mentioned quotient.
Percentage NEFA suppression (NEFA suppr ) has been calculated as 100 × (NEFA 1 -NEFA 2 )/(NEFA 1 -NEFA 3 ), NEFA 1 , NEFA 2 and NEFA 3 being the NEFA concentrations of the steady-state phase of the first, second and third step of the clamp respectively.
Analytical procedures. NEFA were determined using the NE-FAC test (Wako Chemicals GmbH, Neuss, Germany) and immunoreactive insulin and C-peptide concentration in plasma with a radioimmunoassay method (Medgenix, Brussels respectively, Biolab, Brussels, Belgium). Glycated haemoglobin (HbA 1c ) was measured by HPLC (Bio-Rad, Richmond, Calif., USA). Lipoprotein profile was assessed by density gradient ultracentrifugation [26] . Plasma triglyceride concentration was determined with GPO-PAP triglyceride reagent (Boehringer Mannheim, Mannheim, FRG). Plasma glucagon concentration was measured by a specific pancreas glucagon radioimmunoassay (Daiichi, Tokyo, Japan). Apo A1 and Apo B were assessed by rate immunonephelometry using an automated Beckman array analyser (Beckman Instruments). Plasminogen activator inhibitor type 1 antigen (PAI-1-ag) was determined by an ELI-SA method and active PAI-1-ag by an immunoassay specific for the determination of active PAI-1 (Organon Teknika, Turnhout, Belgium).
Tissue type plasminogen activator antigen (t-PA-ag) was measured by immunoassay (Imulyse; Biopool, Umea, Sweden) [27] and activity (t-PA-act.) by a bioimmunoassay (Coatest BIA t-PA, Chromogenix, Mö lndal, Sweden) [28] . The PAI-t-PA complex was measured using an immunoassay (Thrombonostika; Organon Teknika, Boxtel, The Netherlands). Blood samples for assessment of fibrinolysis were collected in Stabilyte tubes to prevent binding of t-PA to PAI-1 [29] .
Statistical analysis. The adequacy of the randomization was assessed by comparing the two treatment groups at baseline using the Mann-Whitney U-Test. The same test was used to assess treatment group differences (tgd) in changes from baseline. Correlation analysis was performed with the Spearman rank correlation test. We used the SOLO 4.0 statistical program (J. Hintze; BMDP Statistical Software, Los Angeles, Calif., USA).
Results
The baseline values and the effects of treatment on insulin resistance, lipids, lipoprotein profile and fibrinolysis are summarized in Tables 1, 2 and 3 respectively. The two study groups did not significantly differ regarding age, BMI, WHR, duration of diabetes, HbA 1c , parameters of insulin resistance, parameters of lipoprotein profile and fibrinolysis.
Hypertension was found in 25 % of the patients (i. e. systolic pressure > 170 and diastolic pressure > 90 mm Hg), 33 % hypertriglyceridaemia (i. e. triglyceride concentration > 2 mmol/l) and 80 % visceral obesity (i. e. WHR > 0.90). All patients had a creatinine clearance over 50 ml/min and microalbuminuria was less than 20 m g/min. None of the patients dropped out of the study. Compliance was checked by measurement of plasma oestradiol levels at the second visit. These levels ranged from 106 to 670 pmol/l in the drug treated group and they were very low or not detectable in the placebo group. Blinding was maintained throughout the Fig. 1 a, b. Comparison of the effect of 6 weeks oestrogen treatment compared to placebo on hepatic glucose production suppression in an euglycaemic hyperinsulinaemic clamp in NIDDM patients with fasting normotriglyceridaemia (K 2.0 mmol/l; NTG) or hypertriglyceridaemia (> 2.0 mmol/l; HTG) study. No significant group-difference was found in treatment related complaints, but in the end all patients guessed the right allocation of treatment group. The total energy intake and dietary composition in terms of protein, fat and carbohydrate content did not differ in the two treatment groups. Table 1 ). The body mass index (BMI) increased by 1.5 % during oestrogen treatment and by 0.7 % during placebo (treatment group difference (tgd) p = 0.04). No difference in change of WHR was found between the two treatment groups.
Insulin resistance (
The decrease in HbA 1c in the oestrogen treated group from 8.7 to 8.1 % (mean change − 0.66 ± 0.67) was more than the decrease from 8.1 to 7.7 % (mean change − 0.34 ± 0.45) in the placebo group (tgd p < 0.03). ) (tgd p < 0.04) ( Table 1) . This was most pronounced in the NTG group (tgd p < 0.002, Fig. 1 a) . In the HTG group no significant difference in treatment effect was found (tgd p = 0.47, Fig. 1 b) . The HGP suppr was significantly greater in the NTG than in the HTG group. The plasma level of glucagon, of C-peptide, the WBGU and the percentage of NEFA suppression changed in a comparable way in both groups, with no differences between the NTG and HTG groups. Before ERT, HbA 1c was not correlated with HGP or HGP suppr . This was also true for the change in HbA 1c during ERT and the change in HGP and HGP suppr .
Lipids, lipoproteins and apolipoproteins (Table 2).
Plasma triglyceride levels did not change significantly in either of the two treatment groups, not even in the HTG patients. The same was true for VLDL-cholesterol. Plasma cholesterol concentration changed only slightly, while the LDL-cholesterol levels in the ERT group decreased by 14 % compared to an increase of 2 % in the control group (tgd p = 0.0001). Concomitantly, the plasma apo B levels decreased by 10 % compared to an increase by 2 % respectively (tgd p = 0.001). HDL-cholesterol increased by 22 % compared to 3 % (tgd p < 0.0002). This change in HDLcholesterol level was mainly due to an increase in the less dense subfraction HDL 2 raising it by 49 % compared to 5 % (tgd p < 0.0001). No significant change was found in HDL 3 -cholesterol concentration. Apo A1 was raised by 16 % compared to 3 % (tgd p = 0.0001). No effect in the mean density of the LPL peak or on the oxidisability of LDL [30] was seen.
Fibrinolysis (Table 3
). Both total PAI-1 antigen and active PAI-1 antigen concentration decreased significantly during ERT compared with the placebo group (both tgd p < 0.05). The change in t-PA activity, t-PA antigen and in the PAI-t-PA complex concentration did not differ between treatment groups. Values are mean ± SD. The p -values indicate the probability that the mean baseline values (p baseline ) or the change in the two treatment groups (p change ) are identical
Discussion
The results of this study demonstrate for the first time that during short term oral ERT the control of NIDDM improves, as indicated by a decrease in HbA 1c . Our study indicates that among the three main sites of insulin resistance, the liver, skeletal muscle and adipose tissue [1] , the liver (increased HGP suppression) is the major site of improvement of diabetic control during short term ERT. Inhibition of glucagon induced glycogenolysis, as has been shown in ovariectomized mice [16] or an inhibition of alpha-cell function, causing a fall of glucagon secretion [15] may be involved. We were not aware of the plasma glucagon levels in the portal blood in our patients, but the peripheral glucagon levels and their changes were similar in the two treatment groups. Values are mean ± SD. The p -values indicate the probability that the mean baseline values (p baseline ) or the change in the two treatment groups (p change ) are identical
We measured basal HGP after normalizing blood glucose values during the night preceeding the clamp to obtain comparable measurements. HGP is influenced by the blood glucose level, which was sometimes over 10 mmol/l on the evening preceding the study.
We found that the HGP suppression by insulin was not affected by ERT in HTG patients, while the suppression was strongly enhanced in NTG patients (tgd p < 0.002). It may be assumed that the increase of triglyceride synthesis during ERT [31] decreases the availability of NEFA for beta-oxidation. Beta-oxidation provides "fuel" for gluconeogenesis, but is rapidly saturated. It may be that in HTG patients due to the increased levels of NEFA, beta-oxidation is already saturated by high substrate availability so that eventual changes in substrate availability are not reflected in changed gluconeogenesis whereas in NTG patients the lower NEFA concentrations allow changes to become visible. An effect of ERT on intracellular availability of NEFA in mitochondria is not known.
Another source of fatty acids for the liver are core remnants of triglyceride rich lipoproteins and HDL 2 particles after they have been attacked by hepatic lipase. Oral administration of oestrogens inhibits hepatic lipase activity [32] . Thus, a reduced NEFA influx from this source may also have contributed to the improved HGP suppr especially in NTG patients. Although the BMI was significantly increased in the ERT group as compared to the placebo group the WHR did not change. The WHR is a measure of abdominal obesity. An increased NEFA release from abdominal fat is important in the insulin resistance syndrome [2] . This is supported by our baseline data, i. e. WHR (r s = − 0.49, p < 0.002) and BMI (r s = − 0.45 p < 0.005) were negatively correlated with HGP suppr .
Insulin resistance can also be caused by reduced blood flow in skeletal muscle and reduced capillary density [1, 33, 34] . However, we could not demonstrate an increase in WBGU during ERT. The effect of oestrogens on the re-esterification of NEFA with glycerol phosphate in adipose tissue, a site of insulin resistance [1] , is unknown.
The change in plasma lipids and lipoproteins from baseline is in accordance with earlier reports on nondiabetic postmenopausal women [22] . The decrease of cholesterol in plasma is a reflection of the lowering of LDL-cholesterol. This was paralleled by a decrease in apo B concentration and may be explained by an increased LDL-cholesterol and apo B catabolism in liver, probably due to an increased number of apo LDL recetpors during ERT [31] . The effects on HDL-cholesterol were mainly due to an increase of its less dense, variable part, the HDL 2 subfraction. This may be explained by suppression of hepatic lipase activity by ERT [31] . Moreover, the increase in HDL was accompanied by a significant increase of apo A1 concentration probably by increased apo AI synthesis in the liver [35] . Although oestrogens enhance triglyceride synthesis in the liver, producing large "fluffy-puffy" VLDL particles [22] , we did not find an increase in plasma VLDL triglyceride, or in VLDL-cholesterol concentration.
A high PAI-1 concentration and activity are associated with insulin resistance [5] [6] [7] . The lowering fits in the pattern of other changes observed during ERT, but the mechanism is not clear. Kroon et al. [23] demonstrated that ERT can induce a decrease in the plasma concentration of PAI-1 in non-diabetic postmenopausal women. During treatment with lowdose oral contraceptives a 50 % decrease in PAI-1 has been observed [36] . We found a decrease in both active and total PAI-1 levels in postmenopausal women with NIDDM, suggesting an improvement of fibrinolysis.
Oestrogen replacement therapy is increasingly prescribed in postmenopausal women for various reasons. We studied the risk factors influenced by unopposed oestrogens. However, in practice combined therapy with progestogens is prescribed to minimize oestrogen-induced risk of endometrial carcinoma in women with an intact uterus. The effect of progestogens remains to be established. In diabetic women ERT is more reluctantly used [24] because of the presumed negative effects of oestrogens on carbohydrate and lipid metabolism [25] . A long term study on the effects of hormone replacement therapy among postmenopausal women with NIDDM should be performed before a more liberal policy is advisable.
